Clinical Trials Update from the European Society of Cardiology Congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE

[1]  J. Nunnelee.  Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572. , 2008 .

[2]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[3]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[4]  C. Pepine,et al.  Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). , 2007, European heart journal.

[5]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[6]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[7]  Jean-Claude Tardif,et al.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. , 2005, European heart journal.

[8]  K. Fox,et al.  The EUROPA Trial: Design, Baseline Demography and Status of the Substudies , 2001, Cardiovascular Drugs and Therapy.

[9]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.